Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda-Reference-Cited by-同舟云学术

Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda

Published:2024-02-01 Issue:2 Volume:1 Page:83-89
ISSN:3005-7590
Container-title:IJTLD OPEN
language:en
Short-container-title:IJTLD OPEN

Author:

Musinguzi A.¹,Aschmann H. E.²,Kadota J. L.³,Nakimuli J.⁴,Welishe F.⁴,Kakeeto J.⁵,Namale C.⁵,Akello L.⁴,Nakitende A.⁴,Berger C.⁶,Katamba A.⁷,Tumuhamye J.⁸,Kiwanuka N.⁸,Dowdy D. W.⁹,Cattamanchi A.¹⁰,Semitala F. C.¹¹

Affiliation:

1. Infectious Diseases Research Collaboration, Kampala, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda;

2. Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA, Department of Epidemiology and Biostatistics, and, Center for Tuberculosis, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA;

3. Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA, Center for Tuberculosis, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA;

4. Infectious Diseases Research Collaboration, Kampala,

5. Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;

6. Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA, Center for Tuberculosis, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA;

7. Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;, Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda;

8. School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda;

9. Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;

10. Center for Tuberculosis, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA;, Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;, Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, CA, USA;

11. Infectious Diseases Research Collaboration, Kampala, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda, Makerere University Joint AIDS Program, Kampala, Uganda

Abstract

<sec id="st1"><title>BACKGROUND</title>Both 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP vs. 3HP among PLHIV.</sec><sec id="st2"><title>METHODS</title>In a cross-sectional survey among PLHIV at an HIV clinic in Kampala, Uganda, participants were randomly assigned to a hypothetical scenario of receiving 1HP or 3HP. Participants rated their level of perceived intention and confidence to complete treatment using a 0–10 Likert scale, and chose between 1HP and 3HP.</sec><sec id="st3"><title>RESULTS</title>Among 429 respondents (median age: 43 years, 71% female, median time on ART: 10 years), intention and confidence were rated high for both regimens. Intention to complete treatment was rated at least 7/10 by 92% (189/206 randomized to 1HP) and 93% (207/223 randomized to 3HP). Respectively 86% (178/206) and 93% (208/223) expressed high confidence to complete treatment. Overall, 81% (348/429) preferred 3HP over 1HP.</sec><sec id="st4"><title>CONCLUSIONS</title>Both 1HP and 3HP were highly acceptable regimens, with 3HP preferred by most PLHIV. Weekly, rather than daily, dosing appears preferable to shorter duration of treatment, which should inform scale-up and further development of short-course regimens for TB prevention.</sec>

Publisher

International Union Against Tuberculosis and Lung Disease

Reference14 articles.

1. The CFIR Card Game: a new approach for working with implementation teams to identify challenges and strategies

2. Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study

3. Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru

4. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons

5. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection